Is ImClone Out of the Woods?

Is ImClone Out of the Woods?
If the FDA approves its Erbitux anticancer treatment, as S&P expects, the biotech’s volatile stock should be set for solid growth

Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.